Zentalis Pharmaceuticals (ZNTL) News Today $3.47 -0.48 (-12.15%) (As of 11/15/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period Zentalis Pharmaceuticals (NASDAQ:ZNTL) Earns Buy Rating from HC WainwrightNovember 17 at 2:46 AM | americanbankingnews.comWedbush Expects Higher Earnings for Zentalis PharmaceuticalsNovember 16 at 1:17 AM | americanbankingnews.comZentalis price target lowered to $8 from $12 at GuggenheimNovember 15 at 4:13 PM | markets.businessinsider.comGuggenheim Cuts Zentalis Pharmaceuticals (NASDAQ:ZNTL) Price Target to $8.00Guggenheim decreased their price objective on shares of Zentalis Pharmaceuticals from $12.00 to $8.00 and set a "buy" rating for the company in a report on Friday.November 15 at 2:15 PM | marketbeat.comCautious Hold on Zentalis Pharmaceuticals Amid Strategic Shifts and Safety ConcernsNovember 15 at 9:10 AM | markets.businessinsider.comZentalis Pharmaceuticals: Hold Rating Amid Leadership Changes and Awaited Strategic ClarityNovember 15 at 9:10 AM | markets.businessinsider.comZentalis Pharmaceuticals (NASDAQ:ZNTL) Earns "Buy" Rating from HC WainwrightHC Wainwright reissued a "buy" rating and issued a $20.00 price objective on shares of Zentalis Pharmaceuticals in a research note on Friday.November 15 at 8:21 AM | marketbeat.comWhat is Wedbush's Forecast for ZNTL FY2024 Earnings?Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL - Free Report) - Investment analysts at Wedbush boosted their FY2024 earnings per share estimates for shares of Zentalis Pharmaceuticals in a research note issued on Tuesday, November 12th. Wedbush analyst R. Driscoll now expects that the company will pNovember 15 at 6:03 AM | marketbeat.comZentalis Pharmaceuticals: Strong Leadership and Promising Clinical Developments Justify Buy RatingNovember 14 at 8:05 AM | markets.businessinsider.comZentalis Pharmaceuticals Announces New Leadership and Strategy ShiftNovember 14 at 3:03 AM | markets.businessinsider.comZentalis appoints Eastland as CEO, Bruns as CMO, Myers as ChairpersonNovember 13, 2024 | markets.businessinsider.comZentalis Pharmaceuticals Adds New Executives as Efforts Around Azenosertib SharpenNovember 13, 2024 | marketwatch.comGSA Capital Partners LLP Raises Stock Holdings in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL)GSA Capital Partners LLP raised its position in shares of Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL - Free Report) by 138.5% during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 608,585 shares of the company's stock after purchasing an additiNovember 12, 2024 | marketbeat.comZentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Receives $10.78 Consensus Price Target from AnalystsNovember 7, 2024 | americanbankingnews.comZentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Given Average Rating of "Hold" by BrokeragesShares of Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL - Get Free Report) have earned an average rating of "Hold" from the ten ratings firms that are covering the company, Marketbeat Ratings reports. Seven investment analysts have rated the stock with a hold recommendation and three have issued a bNovember 4, 2024 | marketbeat.comZentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)November 1, 2024 | globenewswire.comState Street Corp's Strategic Reduction in Zentalis Pharmaceuticals HoldingsOctober 18, 2024 | finance.yahoo.comSeveral Insiders Invested In Zentalis Pharmaceuticals Flagging Positive NewsOctober 15, 2024 | uk.finance.yahoo.comShort Interest in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Drops By 26.2%Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL - Get Free Report) was the target of a large drop in short interest in the month of September. As of September 30th, there was short interest totalling 8,640,000 shares, a drop of 26.2% from the September 15th total of 11,700,000 shares. Based on an average daily trading volume, of 1,760,000 shares, the days-to-cover ratio is currently 4.9 days.October 12, 2024 | marketbeat.comZentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Given Average Recommendation of "Hold" by BrokeragesShares of Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL - Get Free Report) have been given a consensus recommendation of "Hold" by the ten analysts that are covering the firm, MarketBeat reports. Seven analysts have rated the stock with a hold rating and three have assigned a buy rating to the compOctober 10, 2024 | marketbeat.comFMR LLC Adjusts Its Stake in Zentalis Pharmaceuticals IncOctober 7, 2024 | gurufocus.comZentalis Pharma (NASDAQ:ZNTL) Stock, Short Interest ReportOctober 4, 2024 | benzinga.comZentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Holdings Raised by Renaissance Technologies LLCRenaissance Technologies LLC lifted its stake in shares of Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL - Free Report) by 152.6% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 661,682October 1, 2024 | marketbeat.comDecheng Capital LLC Buys 970,859 Shares of Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL)Decheng Capital LLC lifted its stake in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL - Free Report) by 46.2% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 3,070,442 shares of the company's stock after buying an addiSeptember 26, 2024 | marketbeat.comXTX Topco Ltd Has $730,000 Holdings in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL)XTX Topco Ltd lifted its holdings in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL - Free Report) by 1,581.9% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 178,465 shares of the company's stock after purchasing aSeptember 23, 2024 | marketbeat.comZentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Shares Sold by Federated Hermes Inc.Federated Hermes Inc. lowered its stake in shares of Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL - Free Report) by 75.9% during the second quarter, according to its most recent Form 13F filing with the SEC. The fund owned 482,481 shares of the company's stock after selling 1,516,219 shares during tSeptember 21, 2024 | marketbeat.comBiotech Stock Roundup: GILD, NUVL Stocks Surge on Study Data, MRNA Down on UpdatesSeptember 19, 2024 | msn.comFDA lifts partial clinical hold on Zentalis Pharma’s cancer WEE1 inhibitorSeptember 18, 2024 | msn.comMaintaining Hold on Zentalis Pharmaceuticals Amidst Positive Regulatory Developments and Upcoming Clinical MilestonesSeptember 18, 2024 | markets.businessinsider.comStifel Nicolaus Keeps Their Buy Rating on Zentalis Pharmaceuticals (ZNTL)September 18, 2024 | markets.businessinsider.comZentalis Pharma (NASDAQ:ZNTL) Stock Quotes, Forecast and News SummarySeptember 17, 2024 | benzinga.comKuehn Law Encourages Investors of Zentalis Pharmaceuticals, Inc. to Contact Law FirmSeptember 16, 2024 | prnewswire.comZentalis Shares Rise After U.S. FDA Lifts Hold on Azenosertib StudiesSeptember 16, 2024 | marketwatch.comWhy Zentalis Pharmaceuticals Is Rising In Pre-market?September 16, 2024 | markets.businessinsider.comZentalis Pharmaceuticals (NASDAQ:ZNTL) Stock Rating Reaffirmed by OppenheimerOppenheimer reaffirmed an "outperform" rating and set a $20.00 price target on shares of Zentalis Pharmaceuticals in a research report on Monday.September 16, 2024 | marketbeat.comTraders Buy High Volume of Zentalis Pharmaceuticals Call Options (NASDAQ:ZNTL)Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL - Get Free Report) saw some unusual options trading on Monday. Investors purchased 3,891 call options on the company. This represents an increase of approximately 5,886% compared to the average volume of 65 call options.September 16, 2024 | marketbeat.comFDA Removes Partial Hold On Zentalis Pharmaceuticals' Azenosertib Studies In Patients With Gynecological CancersSeptember 16, 2024 | benzinga.comZentalis Pharmaceuticals Announces FDA Has Lifted Partial Clinical Hold on Azenosertib StudiesSeptember 16, 2024 | globenewswire.comTD Asset Management Inc Decreases Stake in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL)TD Asset Management Inc lowered its holdings in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL - Free Report) by 60.3% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 102,880 shares of the company's stock after sellingSeptember 16, 2024 | marketbeat.comZentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Receives Average Recommendation of "Hold" from AnalystsZentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL - Get Free Report) has received a consensus recommendation of "Hold" from the ten ratings firms that are currently covering the firm, Marketbeat reports. Seven research analysts have rated the stock with a hold rating and three have assigned a buy ratingSeptember 15, 2024 | marketbeat.comZentalis Pharmaceuticals to Present Preclinical Azenosertib Data at ESMO 2024September 9, 2024 | globenewswire.comZentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)September 3, 2024 | globenewswire.comZentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Receives Average Rating of "Hold" from AnalystsZentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL - Get Free Report) has earned a consensus recommendation of "Hold" from the ten brokerages that are covering the firm, MarketBeat reports. Seven equities research analysts have rated the stock with a hold rating and three have issued a buy rating on theAugust 21, 2024 | marketbeat.comNewman Ferrara LLP Announces Corporate Governance Investigation of Zentalis Pharmaceuticals, Inc. - ZNTLAugust 20, 2024 | stockhouse.comZentalis Pharmaceuticals, Inc. (ZNTL) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged WrongdoingsAugust 15, 2024 | globenewswire.comQ3 2024 EPS Estimates for Zentalis Pharmaceuticals, Inc. Cut by Analyst (NASDAQ:ZNTL)Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL - Free Report) - Investment analysts at HC Wainwright decreased their Q3 2024 earnings per share (EPS) estimates for shares of Zentalis Pharmaceuticals in a research report issued on Monday, August 12th. HC Wainwright analyst A. Fein now anticipates thaAugust 15, 2024 | marketbeat.comZentalis Pharmaceuticals, Inc. Expected to Earn Q3 2024 Earnings of ($0.86) Per Share (NASDAQ:ZNTL)Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL - Free Report) - Equities researchers at Wedbush increased their Q3 2024 earnings per share (EPS) estimates for shares of Zentalis Pharmaceuticals in a note issued to investors on Monday, August 12th. Wedbush analyst R. Driscoll now forecasts that the cAugust 14, 2024 | marketbeat.comWedbush Upgrades Zentalis Pharmaceuticals (ZNTL)August 13, 2024 | msn.comOptimistic Outlook for Zentalis Pharmaceuticals Amidst Clinical Progress and Market OpportunitiesAugust 12, 2024 | markets.businessinsider.comZentalis Pharmaceuticals (NASDAQ:ZNTL) Rating Reiterated by HC WainwrightHC Wainwright restated a "buy" rating and issued a $20.00 price objective on shares of Zentalis Pharmaceuticals in a report on Monday.August 12, 2024 | marketbeat.com Get Zentalis Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ZNTL and its competitors with MarketBeat's FREE daily newsletter. Email Address 2024's Must-Watch Stocks! (Ad)Welcome to a year of unparalleled opportunities! Dive into our exclusive guide, "9 Stocks Set to Soar," meticulously selected to elevate your portfolio in 2024. Step into 2024 with confidence and the right assets at your fingertips. Click below to opt-in and receive up to two additional free bonus subscriptions. Unsubscribe at any time. [Unlock Your Report Now] ZNTL Media Mentions By Week ZNTL Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ZNTL News Sentiment▼0.620.55▲Average Medical News Sentiment ZNTL News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ZNTL Articles This Week▼193▲ZNTL Articles Average Week Get Zentalis Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ZNTL and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies CYRX News Today PRLD News Today IRWD News Today PAHC News Today IMTX News Today COLL News Today CRGX News Today PRTA News Today CGEM News Today ETNB News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ZNTL) was last updated on 11/17/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredThere is a little known company that is changing warfareWith geo - political instability around the world investors are flocking to defense contract stocks. There...Reticulate | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Zentalis Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Zentalis Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
